Enyo secures EUR 22M to treat viral infections
Enyo Pharma S.A.S. (Paris, France) raised EUR 6 million ($6.5 million) in the first tranche of a planned EUR 22 million ($23.9 million) series A round led by its seed investor, Sofinnova Partners. Morningside and Bpifrance also participated. Enyo is developing compounds for acute and chronic viral infections that aim to disrupt cellular functions essential for virus replication by targeting the interactions between viral and human proteins.
Enyo's lead program, EYP001, is a farnesoid X receptor (FXR; NR1H4) agonist in development for HBV. In 2014, the company's co-founders from the Institut National de la Sante et de la Recherche Medicale (INSERM) showed that modulation of FXR activity controlled HBV protein synthesis. Enyo licensed rights to the compound from Poxel S.A. (Euronext:POXEL) last year to treat infectious indications. ...